Overview

Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II pilot study to evaluate engraftment and toxicity of patients with non-malignant diseases using a reduced intensity conditioning regimen in the setting of allogeneic transplant for non malignant diseases. Bone Marrow or cord blood will be acceptable as a stem cell source. Recently, reduced intensity conditioning (RIC) regimens have been used for both adult patients with leukemias and pediatric patients with non-malignant diseases. These regimens are better tolerated, resulting in less transplant related morbidity and mortality. Stable mixed chimerism, while insufficient for eradication of leukemias, may be sufficient to cure patients with non-malignant diseases.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital of Philadelphia
Treatments:
Alemtuzumab
Busulfan
Cyclosporine
Cyclosporins
Fludarabine
Fludarabine phosphate
Melphalan